AuraGain and iGel Crossover Comparison

NCT02644837 · Status: TERMINATED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 2

Last updated 2017-12-26

No results posted yet for this study

Summary

This study will look at key performance indicators of 2 supraglottic airway devices in anaesthetised adults in a crossover manner.

Conditions

  • Airway Management
  • Laryngeal Mask Airway

Interventions

DEVICE

Insertion of Ambu AuraGain laryngeal mask airway and Igel

Insertion of Ambu AuraGain and iGel laryngeal mask airways in accordance with manufacturer instruction

DEVICE

Fibreoptic assessment with Ambu A-scope

Passage of Ambu a-scope fibrescope down shaft of laryngeal mask airway and assessment of alignment with glottis in relation to amount of glottis that is easily visualised

DEVICE

Ability to insert nasogastric tube

Passage of nasogastric tube down the gastric drainage channel of the device in accordance with manufacturer guidance

DEVICE

Measurement of OLP

Measurement of OLP by closing the adjustable pressure limiting valve against a constant fresh gas flow rate of 3 litres/minute

DEVICE

Ability to perform positive pressure ventilation

The ability to deliver 6 mls/kg volumes breaths by means of positive pressure ventilation will be assessed

DEVICE

Assessment of ease of insertion

Ease of insertion will be subjectively assessed by operator in relation to presence and nature of resistance to insertion of the device

DEVICE

Record number of manipulations

The number of manipulations/adjustments will be recorded for the second device only for the remainder of the device use during surgery until the patient wakes.

DEVICE

Assessment of device related trauma

Observation and assessment of any trauma caused by the insertion of the first device used

Sponsors & Collaborators

  • NHS Tayside

    lead OTHER_GOV

Principal Investigators

  • Simon M Crawley, MBChB FRCA · Consultant Anaesthetist

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-10-31
Primary Completion
2017-05-31
Completion
2017-08-31

Countries

  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02644837 on ClinicalTrials.gov